Citations

Clear

9383 citation(s) found for "Thomas, PS".

Cancer-Associated Venous Thromboembolic Disease, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
Streiff, Michael B. , Holmstrom, Bjorn, Angelini, Dana E. , Ashrani, Aneel A. , Diep, Robert , Fogerty, Annemarie E., Gallastegui, Nicolas , Gangaraju, Radhika , Rojas‐Hernandez, Cristhiam M. , Goldhaber, Samuel Z. , Kubal, Timothy, Leavitt, Andrew D., Mann, Janelle , Mantha, Simon , Morton, Colleen , Nester, Alex, O’Brien, Andrew , Ranade, M. , Salmasi, Amirali , Schaefer, Jordan K. , Williams, Eliot C., Wun, Theodore, Nguyen, Jamie , Freedman-Cass, Deborah A., Sliker, Bailee , Ashrani, Aneel, Schaefer, Jordan K , Buckner, Tyler W. , Fertrin, Kleber Yotsumoto , Ibrahim, Ibrahim , Leavitt, Andrew D. , Lim, Ming Y , Mann, Janelle, O’Brien, Andrew, Ortel, Thomas L. , Pine, Alexander B. , Pishko, Allyson M. , Wool, Geoffrey D. , Montgomery, Sarah E.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | September 5, 2024 | Volume: 22 | Issue: 7 | Pages: 483-506

10.6004/jnccn.2024.0046 | PMID 39236759 Get It

The NCCN Guidelines for Cancer-Associated Venous Thromboembolic Disease provide strategies for the prevention, diagnosis, and treatment of venous thromboembolism (VTE) in adult patients with cancer. VTE is a common and life-threatening condition in patients with cancer, and its management often requires multidisciplinary efforts. The NCCN panel is comprised of specialists spanning various fields, including cardiology, hematology, medical oncology, internal medicine, interventional radiology, and pharmacology. The content featured in this issue specifically addresses the evaluation and recommended treatment options outlined in the NCCN Guidelines for the diverse subtypes of cancer-associated VTE.
Assessment of the Addition of Oxaliplatin to Fluoropyrimidine-Based Adjuvant Chemotherapy in Patients With High-Risk Stage II Colon Cancer: An ACCENT Pooled Analysis
Chibaudel, Benoist , Raeisi, Morteza , Cohen, Romain , Yothers, Greg , Goldberg, Richard M. , Wolmark, Norman , Yoshino, Takayuki , Schmoll, Hans‐Joachim , George, Thomas J. , Shacham‐Shmueli, Einat , Gramont, Aimery de , Wolmark, Norman , Yoshino, Takayuki , Schmoll, Hans-Joachim , George, Thomas J , Shi, Qian , André, Thierry , De Gramont, Aimery , Yothers, Greg , Chibaudel, Benoist , Cohen, Romain , Bachet, Jean‐Baptiste , Kerr, Rachel , Lonardi, Sara , Shi, Qian , André, Thierry

Mayo Clinic

Journal of Clinical Oncology | September 4, 2024 | Volume: 42 | Issue: 35 | Pages: 4187-4195

10.1200/jco.24.00394 | PMID 39231393 Get It

PURPOSE The adjuvant treatment for stage III colon cancer (CC) is chemotherapy combining fluoropyrimidine (FP) and oxaliplatin (OX). FP regimen plus OX (FPOX) may benefit in high-risk stage II CC. We performed a pooled analysis of pivotal MOSAIC and C-07 studies evaluating FPOX for the treatment of high-risk stage II CC according to prognostic factors, number of high-risk factors, and current clinicopathologic risk classification on the basis of T stage, tumor perforation, and number of lymph nodes examined. PATIENTS AND METHODS One thousand five hundred and ninety-five patients with stage II CC receiving FP or FPOX were pooled. The overall survival (OS) benefit of OX was analyzed using Kaplan-Meier curves and unadjusted Cox models stratified by study. Three thousand and fifty-nine patients with stage III CC were used only for interaction tests between the allocated chemotherapy and stage. RESULTS In the pooled analysis of stage II patients, independent prognostic factors in multivariable analysis were sex, age, perforation/obstruction, and tumor sidedness. There was a significant interaction in OS between stage and allocated chemotherapy with hazard ratios (HRs) of 1.03 for stage II (95% CI, 0.82 to 1.29; P = .813) and 0.82 for stage III (95% CI, 0.73 to 0.92; P = .001; P int = .073). There was no benefit from the addition of OX to FP for any of the prognostic factors. The number of high-risk factors tested was not predictive of OX benefit. According to the currently agreed clinicopathologic risk classification, no OS benefit of OX was observed, as HR was 0.86 (95% CI, 0.63 to 1.18; P = .349). CONCLUSION No OS benefit of adjuvant OX was found in high-risk stage II CC, regardless of the definition used to characterize tumors as having a high risk for recurrence. Hence, our analysis suggests that OX should not be the standard of care for adjuvant chemotherapy for stage II CC, even in high-risk patients.
Mitigating the Risk of Instability After Reverse Shoulder Arthroplasty
Bindi, Victoria E. , Buchanan, Timothy R. , Cueto, Robert J. , Hones, Keegan M. , Wright, Thomas W. , King, Joseph J. , Hao, Kévin A. , Schoch, Bradley S , King, Joseph J , Hao, Kevin A , Hones, Keegan M , Schoch, Bradley S.

Mayo Clinic

JBJS Reviews | September 4, 2024 | Volume: 12 | Issue: 9 | Pages: No page available

10.2106/jbjs.rvw.24.00095 | PMID 39226391 Get It

» Instability and dislocation after reverse shoulder arthroplasty may occur in up to 31% of patients. » Clinical risk factors for instability include younger age, male sex, increased body mass index, preoperative diagnosis of proximal humerus fracture or rotator cuff pathology, history of instability of the native shoulder or after surgery, and a medical history of Parkinson’s disease. » Patients with rheumatoid arthritis and decreased proximity to the coracoid may also be at greater risk. » In patients at a high risk of instability, surgeons should consider a more lateralized prosthesis (particularly in patients with an incompetent rotator cuff), repairing the subscapularis (particularly when using a medialized prosthesis), and upsizing the glenosphere (>40 mm in male and 38–40 mm in female patients). » While potentially useful, less evidence exists for the use of a constrained liner (particularly with a lateralized glenosphere and/or in low-demand patients) and rotating the polyethylene liner posteriorly to avoid impingement. Level of Evidence: Level V . Narrative Review. See Instructions for Authors for a complete description of levels of evidence.
Current state of the pain medicine match: perspective and an eye to the future
Aggarwal, Anuj , Barad, Meredith , Chai, Nu Cindy , Furnish, Timothy , Mishra, Puneet , Kohan, Lynn , Moeschler, Susan M. , Reddy, Rajiv , Yalamuru, Bhavana , Aggarwal, Anuj Kailash , Moeschler, Susan, Reddy, Rajiv , Barad, Meredith J

Mayo Clinic

Regional Anesthesia & Pain Medicine | September 4, 2024 | Volume: 50 | Issue: 12 | Pages: 982-984

10.1136/rapm-2024-105770 | PMID 39231574 Get It

The National Resident Matching Program (NRMP) for pain medicine fellowships marked its 10th anniversary in 2023, coinciding with growing discussions within the Association of Pain Program Directors (APPD) regarding the program’s future in the context of a recent decline of applicants into pain medicine. This letter explores the rationale behind reassessing the NRMP’s utility for pain medicine, examining historical and current trends, and considering the implications of withdrawing from the match. Despite a recent decline in applicants and an increase in unfilled positions, the APPD advocates for continued participation in the match. The match ensures equitable and stable recruitment, preventing the chaotic pre-match environment of competitive, early offers. Data from similar specialties highlight the pitfalls of non-match systems, such as increased applicant pressure and reduced program visibility. The APPD supports maintaining the NRMP match while implementing reforms like preference signaling to address evolving challenges. The APPD aims to preserve the match’s benefits and ensure a stable future for pain medicine fellowship recruitment.
Bridging the gap: Multi‐omics profiling of brain tissue in Alzheimer's disease and older controls in multi‐ethnic populations
Reddy, Joseph S. , Heath, Laura , Linden, Abby Vander , Allen, Mariet , Lopes, Kátia de Paiva , Wang, Erming , Poehlman, William L. , Quicksall, Zachary , Runnels, Alexi , Duong, Duc M. , Yin, Luming, Xu, Kaiming , Modeste, Erica , Dammer, Eric B. , Ping, Lingyan , Oatman, Stephanie R., Scanlan, Jo, Ho, Charlotte C.G. , Carrasquillo, Minerva M. , Atık, Merve, Yepez, Geovanna, Mitchell, Adriana O., Nguyen, Thuy , Chen, Xianfeng , Reddy, Hasini, Xiao, Harrison, Seshadri, Sudha , Mayeux, Richard , Beach, Thomas G. , Haroutunian, V., Fox, Edward J., Gearing, Marla , Wingo, Aliza P. , Wingo, Thomas S. , Jager, Philip L. De , Zhang, Bin , Bennett, David A. , Seyfried, Nicholas T. , Greenwood, Anna K. , Ertekin‐Taner, Nilüfer , Bennett, David A. , Ho, Charlotte, Greenwood, Anna K , Seshadri, Sudha , Dammer, Eric B , Wingo, Thomas S , Seifar, Fatemeh , Ma, Yiyi , Wang, Yanling , Shantaraman, Anantharaman , Carrasquillo, Minerva M. , Márquez, David X. , Prokop, Stefan , Lee, Edward B. , Serrano, Geidy E. , Teich, Andrew F. , Lah, James J. , Levey, Allan I. , Dickson, Dennis W. , Barnes, Lisa L.

Mayo Clinic

Alzheimer's & Dementia | August 31, 2024 | Volume: 20 | Issue: 10 | Pages: 7174-7192

10.1002/alz.14208 | PMID 39215503 Get It

Abstract INTRODUCTION Multi‐omics studies in Alzheimer's disease (AD) revealed many potential disease pathways and therapeutic targets. Despite their promise of precision medicine, these studies lacked Black Americans (BA) and Latin Americans (LA), who are disproportionately affected by AD. METHODS To bridge this gap, Accelerating Medicines Partnership in Alzheimer's Disease (AMP‐AD) expanded brain multi‐omics profiling to multi‐ethnic donors. RESULTS We generated multi‐omics data and curated and harmonized phenotypic data from BA ( n = 306), LA ( n = 326), or BA and LA ( n = 4) brain donors plus non‐Hispanic White ( n = 252) and other ( n = 20) ethnic groups, to establish a foundational dataset enriched for BA and LA participants. This study describes the data available to the research community, including transcriptome from three brain regions, whole genome sequence, and proteome measures. DISCUSSION The inclusion of traditionally underrepresented groups in multi‐omics studies is essential to discovering the full spectrum of precision medicine targets that will be pertinent to all populations affected with AD. Highlights Accelerating Medicines Partnership in Alzheimer's Disease Diversity Initiative led brain tissue profiling in multi‐ethnic populations. Brain multi‐omics data is generated from Black American, Latin American, and non‐Hispanic White donors. RNA, whole genome sequencing and tandem mass tag proteomicsis completed and shared. Multiple brain regions including caudate, temporal and dorsolateral prefrontal cortex were profiled.
Comprehensive analysis of substernal lead removal: experience from EV ICD Pilot, Pivotal, and Continued Access Studies
Sagi, Venkata, Murgatroyd, Francis , Boersma, Lucas V.A. , Manlucu, Jaimie , Knight, Bradley P. , Leclercq, Christophe , Amin, Anish K. , Birgersdotter‐Green, Ulrika , Chan, Joseph Yat Sun , Roukoz, Henri , Denman, R. , Wiggenhorn, Christopher, Holmes, Thomas R, Lulic, Thomas, Friedman, Paul A. , Biffi, Mauro , Haqqani, Haris , Denman, Russell , Friedman, Paul A , Crozier, Ian , Knight, Bradley P , Boersma, Lucas , Amin, Anish, Biffi, Mauro , Holmes, Thomas R, Crozier, Ian

Mayo Clinic

Europace | August 30, 2024 | Volume: 26 | Issue: 9 | Pages: No page available

10.1093/europace/euae225 | PMID 39210643 Get It

Abstract Aims The extravascular implantable cardioverter-defibrillator (EV ICD) has been shown to be safe and effective for patients at risk of sudden cardiac death, but little is known about EV ICD lead removal in humans. This analysis aimed to characterize the EV ICD lead removal experience thus far. Methods and results This was a retrospective analysis of lead removals from the EV ICD Pilot, Pivotal, and Continued Access Studies. Patients with a successful EV ICD implant who underwent lead removal were included. The main objective was lead removal success. Ancillary objectives included characterizing technique used, procedure complications, and reimplantation status. An EV ICD system was successfully implanted in 347 patients across the 3 studies (25.9% female; 53.4 ± 13.3 years; left ventricular ejection fraction: 39.7 ± 15.9). Of these patients, 29 (8.4%) underwent lead removal with a mean lead dwell time of 12.6 ± 14.3 months (0.2–58.4). The main reason for lead removal was lead dislodgement (n = 9, 31.0%). Lead removal was successful in 27/29 (93.1%) cases [100% (19/19) success rate <1 year and 80% (8/10) success rate >1 year post-implant]. Simple traction was used in 22/26 (84.6%) and extraction tools in 4/26 (15.4%) successful cases where technique was known. No complications were reported for any of the removal procedures. All 11 EV ICD reimplant attempts were successful. Conclusion Complete removal of the EV ICD lead was successful in 93.1% of cases, and simple traction was sufficient in most instances. Based on these results, lead removal from the substernal space was safe and achievable up to 3 years post-implant.
Cancer in Patients With Incidental Asymmetric Oropharynx Positron Emission Tomography Uptake
Armstrong, Michael , O’Byrne, Thomas J., Gottlich, Harrison C. , Tasche, Kendall K. , Moore, Eric J. , Gamez, Mauricio E. , Neben-Wittich, M.A. , Price, Katharine A., Lowe, Val J. , Abel, Kathryn M. Van , O'Byrne, Thomas J, Gamez, Mauricio , Lester, Scott C. , Neben-Wittich, Michelle A, Van Abel, Kathryn M , Burkett, Brian J. , Yin, Linda X. , Price, Daniel L. , Routman, David M. , Daniel, J.

Mayo Clinic

JAMA Otolaryngology–Head & Neck Surgery | August 29, 2024 | Volume: 150 | Issue: 12 | Pages: 1078

10.1001/jamaoto.2024.2556 | PMID 39207815 Get It

ImportanceAsymmetric oropharynx uptake on positron emission tomography (PET)/computed tomography (CT) is a common incidental finding and often prompts otolaryngology referral to rule out malignancy; however, the true risk of malignancy based on this finding is unknown.ObjectiveTo identify the incidence of oropharynx cancer in patients with incidental asymmetric oropharynx PET uptake.Design, Setting, and ParticipantsIn this retrospective cohort study, patients 18 years and older undergoing PET/CT scans at Mayo Clinic between January 2001 and December 2018 were included. Patients with a history or pretest suspicion of oropharynx cancer were excluded. Data were analyzed from March 2021 to December 2023.ExposureBlinded radiologic review of imaging studies, including measurement of maximum standardized uptake values (SUVmax) of the ipsilateral side of concern and contralateral side. Retrospective medical record review for associated clinical data.Main Outcomes and MeasuresThe primary study outcome was the incidence of oropharynx cancer diagnosis in patients with asymmetric oropharynx PET uptake. The primary outcome was formulated before data collection.ResultsOf the 1854 patients identified with asymmetric oropharynx PET uptake, 327 (17.6%) met inclusion criteria. Of these, 173 (52.9%) were male, and the median (range) age was 65.0 (24.8-90.7) years. The mean (SD) follow-up interval was 52.1 (43.4) months. A total of 18 of 327 patients (5.5%) were newly diagnosed with oropharynx cancer. The most common diagnosis was squamous cell carcinoma (n = 9), followed by lymphoma (n = 8), and sarcoma (n = 1). Patients with an incidental diagnosis of oropharynx cancer had higher mean (SD) ipsilateral SUVmax (8.7 [3.7] vs 5.3 [1.9]) and SUVmax ratio (3.0 [1.6] vs 1.6 [0.6]) compared with patients with normal examination findings. SUVmax ratio and difference were found to be good discriminators of oropharynx cancer, with areas under the receiver operating characteristic curve of 86.3% (95% CI, 76.4-94.6) and 85.8% (95% CI, 74.8-94.6), respectively. Patients with a new diagnosis of oropharynx cancer were more likely to have a corresponding CT abnormality than those with normal examination findings (6 of 18 [33%] vs 24 of 295 [8.1%]). Patients with concerning lesions on oropharynx palpation by an otolaryngology health care professional were significantly more likely to be diagnosed with oropharynx cancer compared with patients with normal examination findings (odds ratio, 28.4; 95% CI, 6.6-145.8).Conclusions and RelevanceIn this cohort study, while incidental asymmetric oropharynx PET uptake was common, a new diagnosis of oropharynx cancer was not and potentially results in a large volume of unnecessary referrals and work-up. Using SUVmax ratio, SUVmax difference, and CT correlation may increase the benefit of referral. Patients with a palpable oropharynx lesion and asymmetric oropharynx PET uptake should undergo confirmatory biopsy.
Ide-cel vs standard regimens in triple-class–exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses
Arnulf, Bertrand , Patel, Krina K. , Manier, Salomon , Callander, Natalie S. , Vij, Ravi, Bahlis, Nizar J. , Solomon, Scott R. , Abrahamsen, Ingerid Weum , Broijl, Annemiek , Chen, Christine , Delforge, Michel , Benjamin, Reuben , Iida, Shinsuke , Truppel-Hartmann, Anna, Zhong, Xiaobo , Piasecki, Julia , Eliason, Laurie , Dhanda, Devender , Felten, Jasper, Caia, Andrea, Popa-McKiver, Mihaela, Patel, Krina , Manier, Salomon , Callander, Natalie , Costa, Luciano J , Bahlis, Nizar Jacques , Abrahamsen, Ingerid Weum , Jagannath, Sundar , Pabst, Thomas , Iida, Shinsuke , Berdeja, Jesús G , Giralt, Sergio , Rodriguez-Otero, Paula , Ailawadhi, Sikander , Cavo, Michèle , Nooka, Ajay K. , Costa, Luciano J. , Moreau, Philippe , Baz, Rachid , Jagannath, Sundar , Raje, Noopur , Scheid, Christof , Berdeja, Jesús G. , Giralt, Sergio , Chen, Yanping , Wu, Fan , Cook, Mark , Rodríguez‐Otero, Paula

Mayo Clinic

Blood | August 28, 2024 | Volume: 144 | Issue: 23 | Pages: 2389-2401

10.1182/blood.2024024582 | PMID 39197072 Get It

Abstract Outcomes are poor in triple-class–exposed (TCE) relapsed and refractory multiple myeloma (R/RMM). In the phase 3 KarMMa-3 trial, patients with TCE R/RMM and 2 to 4 prior regimens were randomized 2:1 to idecabtagene vicleucel (ide-cel) or standard regimens (SRs). An interim analysis (IA) demonstrated significantly longer median progression-free survival (PFS; primary end point; 13.3 vs 4.4 months; P < .0001) and higher overall response rate (ORR) with ide-cel vs SRs. At final PFS analysis (median follow-up, 30.9 months), ide-cel further improved median PFS vs SRs (13.8 vs 4.4 months; hazard ratio [HR], 0.49; 95% confidence interval [CI], 0.38-0.63). PFS benefit with ide-cel vs SRs was observed regardless of number of prior lines of therapy, with greatest benefit after 2 prior lines (16.2 vs 4.8 months, respectively). ORR benefit was maintained with ide-cel vs SRs (71% vs 42%; complete response, 44% vs 5%). Patient-centric design allowed crossover from SRs (56%) to ide-cel upon progressive disease, confounding overall survival (OS) interpretation. At IA of OS, median was 41.4 (95% CI, 30.9 to not reached [NR]) vs 37.9 (95% CI, 23.4 to NR) months with ide-cel and SRs, respectively (HR, 1.01; 95% CI, 0.73-1.40); median OS in both arms was longer than historical data (9-22 months). Two prespecified analyses adjusting for crossover showed OS favoring ide-cel. This trial highlighted the importance of individualized bridging therapy to ensure adequate disease control during ide-cel manufacturing. Ide-cel improved patient-reported outcomes vs SRs. No new safety signals were reported. These results demonstrate the continued favorable benefit-risk profile of ide-cel in early-line and TCE R/RMM. This trial was registered at www.ClinicalTrials.gov as #NCT03651128.